H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $50 from $45 and keeps a Buy rating on the shares following the “strong” Q1. Tryngolza beat Q1 Street estimates, driven by pent-up demand, the analyst tells investors in a research note. The firm says the potential severe hypertriglyceridemia expansion could “dramatically” expand the market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Buy Rating Backed by Robust Drug Performance and Strategic Market Expansion
- Ionis Pharmaceuticals price target lowered to $64 from $65 at Guggenheim
- Ionis Pharmaceuticals: Strong Q1 Performance and Future Growth Potential Drive Buy Rating
- Ionis Pharmaceuticals Reports Strong Q1 2025 Results
- Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges